Tirzepatide is a dual GIP and GLP-1 receptor agonist that enhances insulin secretion, reduces appetite and promotes weight loss.
Recommended for:
Studies:
Clinical trials (SURPASS, SURMOUNT) confirmed Tirzepatide’s effectiveness in reducing HbA1c and body weight, showing superiority over GLP-1 receptor agonists.
Administered subcutaneously once a week. The dosage is selected individually by a doctor, starting from the lowest and gradually increasing.
Contraindications:
Side effects:









